Mer Scott
Quiz by , created more than 1 year ago

PHCY320 (Oncology) Quiz on ON10 Lung Cancer, created by Mer Scott on 07/10/2019.

3
0
0
Mer Scott
Created by Mer Scott about 5 years ago
Close

ON10 Lung Cancer

Question 1 of 14

1

Epidemiology​ -
Lung cancer rates worldwide​
Rates in males higher in developed vs. developing countries but decreasing due to tobacco control initiatives ​
Leading cause of -related deaths in NZ (1600 per year)​
1 in 5 people diagnosed have smoked​
Lung cancer incidence and mortality 4x higher in and 3x higher in vs. non-Maori populations​

Drag and drop to complete the text.

    increasing
    cancer
    never
    Maori women
    Maori men

Explanation

Question 2 of 14

1

Which of these is NOT a risk factor for lung cancer?

Select one of the following:

  • Age

  • History or current use of tobacco cigarettes, pipes, cigars

  • Exposure to secondhand smoke​

  • Occupational exposures (asbestos, arsenic, chromium, etc.)​

  • Environmental exposures eg polluted air

  • Family history​

  • HIV

  • Beta carotene supplements in heavy smokers

  • Radiation exposure

  • Exposure to lung cancer patients

Explanation

Question 3 of 14

1

Screening​ - For risk patients.
- scanning - only intervention to influence mortality​
- X-ray and/or sputum cytology has shown

Drag and drop to complete the text.

    Low-dose helical CT
    no benefit ​
    high

Explanation

Question 4 of 14

1

Which of these is not a clinical presentation of lung cancer?

Select one of the following:

  • Hoarseness​

  • Dyspnoea​

  • Weight loss​

  • Malaise​

  • Hemoptysis (blood mixed with sputum)

  • Blood in faeces

Explanation

Question 5 of 14

1

CT scan, chest x-ray, and biopsy are all used for diagnosis of lung cancer.

Select one of the following:

  • True
  • False

Explanation

Question 6 of 14

1

Types of Lung Cancer​

1. Non-Small Cell Lung Cancer ​
% of lung cancers​. Origin from cells​. Includes adenocarcinomas, squamous cell carcinomas, large cell carcinomas​. Staged using ​. Better outcomes​.

2. Small Cell Lung Cancer ​
% of lung cancers . Origin from cells in bronchi. Rarely occurs in ​. Limited vs. Extensive staging​. Rapidly (metastases)​; poor .

Drag and drop to complete the text.

    80-85
    5-20
    epithelial
    nerve producing
    TNM
    survival
    non-smokers
    spreading
    prognosis

Explanation

Question 7 of 14

1

Which of these is NOT a feature of an adverse (poor) prognosis?

Select one of the following:

  • Presence of pulmonary symptoms​

  • Large tumor size (>3cm)​

  • Squamous histology​

  • Metastases to multiple lymph nodes ​

  • Vascular invasion​

Explanation

Question 8 of 14

1

Staging NSCLC​
Stage 0 –
Stage 1 – small tumor (<cm), lymph node involvement or mets​
Stage 2 – small to medium tumor (<3cm or 3-cm), node involvement, no metastases​
Stage 3 – medium to large tumor, more lymph node involvement, no metastases
Stage 4 – any size / lymph node involvement, of metastases

Drag and drop to complete the text.

    carcinoma in situ​
    3
    no
    regional lymph
    presence
    5
    extensive

Explanation

Question 9 of 14

1

Match the stage to the estimated 5 year survival rate. (Randomised order.)
53-60%​ - Stage
77-92%​ - Stage
13-36%​ - Stage
0-10%​ - Stage

Drag and drop to complete the text.

    2
    1
    3
    4

Explanation

Question 10 of 14

1

Match the Tx to the staging.

Stage 0​ -
Stage I​ -
Stage II​ = ?Neoadjuvant CT
Stage III​ - Surgery, Radiation​
Stage IV​ - CT, monoclonal , maintenance therapy, EGFR tyrosine kinase inhibitor (EGFR mutations), ALK inhibitors (ALK translocations), ROS1 inhibitors (ROS1 rearrangements), BRAFV600E and MEK inhibitors (BRAFV600E mutations), immune checkpoint inhibitor, local therapies…

Drag and drop to complete the text.

    Surgery
    Surgery, Radiation​
    Surgery, Radiation, Adjuvant CT,​
    , Adjuvant CT, Neoadjuvant CT,
    Combination
    antibodies

Explanation

Question 11 of 14

1

Treatment – Stage II​

Adjuvant​ (post-primary tx):
- based therapy (5 year survival absolute benefit of 5.4%)​
- Combination drugs include
Neoadjuvant​ (pre primary Tx)
Absolute benefit of 5 year survival of 6% across all stages. ​Largest study (most patient Stage I) showed survival benefit. Controversial.

Drag and drop to complete the text.

    Cisplatin
    vinorelbine, etoposide, vinca alkaloid ​
    no

Explanation

Question 12 of 14

1

Treatment – Stage III​

Adjuvant​ -
Modest survival benefits shown in FRE-IALT and ANITA trials​.
typically regimen of choice .
immunotherapy for patients with no progression after 2 or more cycles of chemoradiation therapy) - interim analysis showed progression-free survival months (durvalumab) vs. 5.6 months placebo (HR 0.52)​.

Drag and drop to complete the text.

    Cisplatin and vinorelbine
    Durvalumab
    16.8

Explanation

Question 13 of 14

1

Cisplatin toxicity
- (stay hydrated)
- Dose dependent
- Severe , loss of appetite and taste
- Myelosuppression

Vinorelbine toxicity
- Peripheral
-
- Neutropenia
- (as are all vinca alkaloids)

Drag and drop to complete the text.

    Nephrotoxicity
    ototoxicity
    nausea and vomiting
    neuropathy
    Constipation
    Vesicant

Explanation

Question 14 of 14

1

SCLC Tx

Limited disease​ standard Tx = (21 day cycle x 4 cycles)​\
Extensive disease​ standard Tx = / Cyclophosphamide (21 day cycle x cycles)​. Can also use cisplatin / etoposide as above​.

Drag and drop to complete the text.

    Cisplatin / Etoposide
    Doxorubicin / Vincristine
    4-6

Explanation